GSK, RSV and Shingles
GSK's Respiratory Syncytial Virus Vaccine Given Together With Shingles Shot Shows Non-Inferior Immune Response In Older Adults
GSK released data from a Phase 3 trial evaluating the co-administration of Arexvy and Shingrix vaccines in adults 50+. The study showed a non-inferior immune response and good safety profiles. The results will support regulatory submissions to the FDA and EMA.
GSK Reports Findings on Coadministered RSV and Shingles Vaccines
Topline results were announced from a phase 3 study assessing the immune response following coadministration of Arexvy and Shingrix.
Good signs for co administration of GSK’s RSV and shingles vaccines
UK drugmaker GSK presented positive Phase III trial data at the European Geriatric Medicine Society Congress. The trial showed that co-administering Arexvy (RSV vaccine) and Shingrix (shingles vaccine) in adults 50+ produced a non-inferior immune response and was well tolerated.
GSK posts late-stage trial win for co-administered RSV and shingles vaccines
GSK (GSK) reached the main goal in a Phase 3 trial for its RSV shot, Arexvy co--administered with Shingles vaccine Shingrix. Read more here.
GSK Sees Positive Results in Trial of Combination RSV, Shingles Vaccine
GSK recorded positive topline data in a late stage trial of its respiratory syncytial virus vaccine combined with a shingles vaccine in treating adults 50 years and older.
GSK Shingles Vaccine in Malaysia: Here’s What You Need to Know
GSK has launched it's Shingles vaccine in Malaysia and here's all you need to know about it. From what it is, to the side effects, for whom and where to get it.
GSK shingles vaccine now available in Malaysia
A vaccine for the prevention of shingles in adults aged 50 and over and those aged 18 and over at increased risk KUALA LUMPUR, Malaysia, Sept. /PRNewswire/ -- GlaxoSmithKline Pharmaceutical Sdn Bhd (GSK) today announced the launch of its Herpes Zoster vaccine,
GSK's RSV vaccine meets main goal when co-administered with shingles shot
British drugmaker GSK said on Wednesday its respiratory syncytial virus (RSV) vaccine, when given together with its shingles shot, met the main goal of a late-stage trial in adults over 50 years of age.
GSK Reports Positive Data From Co-administration Of RSV And Shingles Vaccines
GSK plc (GSK, GSK.L) announced positive topline data from the phase 3 trial in adults 50 years and older evaluating the
GSK shingles vaccine cuts dementia risk
GSK (NYSE:GSK) announced Tuesday that its shingles vaccine, Shingrix ... Citing topline data from its ZOSTER-122 ...
Joplin Globe2d
GSK Announces Positive Topline Data on Co-Administration of AREXVY and SHINGRIX
About the NCT05966090 trial The co-administration study is a phase 3, open-label, multi-country study to assess non-inferiority of immune responses in co-administration of GSK’s RSV and Recombinant ...
Yahoo Finance7d
GSK shingles vaccine now available in Malaysia
13, 2024 /PRNewswire/ -- GlaxoSmithKline Pharmaceutical Sdn Bhd (GSK) today announced the launch of its Herpes Zoster vaccine, Shingrix (MAL24056002ARZ), also known as Recombinant Zoster ...
bernama3d
Shingles May Cause Long-Term Pain In Older People – Expert
PHN is characterised by pain lasting from three months to several years after the rash subsides, and it is also the most ...
Hosted on MSN6mon
This vaccine may help protect against dementia — and it’s already available
But scientists at drugs giant GSK think they may have ... only at those who were given the vaccine in their 70s or older. Shingles is caused by varicella zoster, the virus that causes chickenpox ...